Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

Presentation ACC 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presenter: Michael J. Koren

April 06, 2024

Presentation ACC 2023

A Randomized Trial Assessing The Impact Of Eliminating Copayment For High Value Preventive Medications For Low-income Seniors With Cardiovascular-related Chronic Diseases

Presenter: Braden Manns

March 06, 2023

Presentation ACC 2023

A Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease (PCDS Statin)

Presenter: Salim Virani

March 05, 2023

Presentation ACC 2023

A Cluster-Randomized Trial to Improve Care of Patients in Cardiology Clinics with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease [COORDINATE-Diabetes]

Presenter: Neha J. Pagidipati

March 05, 2023

Presentation ACC 2020

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Presenter: Deepal L. Bhatt

March 30, 2020

Presentation ACC 2018

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease (The CARES Trial)

Presenter: William B. White

March 11, 2018

Advertisement

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

A Randomized Trial Assessing The Impact Of Eliminating Copayment For High Value Preventive Medications For Low-income Seniors With Cardiovascular-related Chronic Diseases

A Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease (PCDS Statin)

A Cluster-Randomized Trial to Improve Care of Patients in Cardiology Clinics with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease [COORDINATE-Diabetes]

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease (The CARES Trial)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content